Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Brainstorm Cell Therapeutics I - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
BCLI
Nasdaq
8731
https://brainstorm-cell.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Brainstorm Cell Therapeutics I
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
- Apr 16th, 2024 10:30 pm
BCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™…
- Apr 11th, 2024 10:27 am
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
- Apr 11th, 2024 10:00 am
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
- Apr 10th, 2024 10:00 am
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
- Apr 9th, 2024 10:00 am
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
- Apr 8th, 2024 10:00 am
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
- Apr 1st, 2024 12:05 pm
BCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS…
- Mar 6th, 2024 11:12 am
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
- Feb 27th, 2024 11:30 am
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
- Feb 23rd, 2024 11:00 am
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
- Feb 13th, 2024 11:30 am
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments
- Dec 26th, 2023 12:30 pm
BrainStorm Issues 2023 Letter to Shareholders
- Dec 20th, 2023 2:00 pm
BCLI: FDA Meeting Provides Clear Path for Planned Phase 3b Trial of NurOwn
- Dec 8th, 2023 9:15 am
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS
- Dec 7th, 2023 1:40 pm
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALS
- Nov 20th, 2023 1:10 pm
BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia
- Nov 17th, 2023 12:00 pm
BCLI: Phase 3b Trial Details to be Discussed with FDA…
- Nov 16th, 2023 2:26 pm
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2023 Earnings Call Transcript
- Nov 15th, 2023 6:53 pm
Q3 2023 Brainstorm Cell Therapeutics Inc Earnings Call
- Nov 15th, 2023 8:29 am
Scroll